These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36720133)

  • 1. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
    Malec L; Peyvandi F; Chan AKC; Königs C; Zulfikar B; Yuan H; Simpson M; Álvarez Román MT; Carcao M; Staber JM; Dunn AL; Chou SC; d'Oiron R; Albisetti M; Demissie M; Santagostino E; Yarramaneni A; Wong N; Abad-Franch L; Gunawardena S; Fijnvandraat K;
    N Engl J Med; 2024 Jul; 391(3):235-246. PubMed ID: 39018533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.
    DiBenedetti D; Neme D; Pan-Petesch B; Willemze A; Wynn T; Kragh N; Wilson A
    Clin Ther; 2024 Dec; 46(12):1016-1023. PubMed ID: 39414418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA
    Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
    Lissitchkov T; Willemze A; Katragadda S; Rice K; Poloskey S; Benson C
    Blood Adv; 2022 Feb; 6(4):1089-1094. PubMed ID: 34794179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efanesoctocog Alfa: First Approval.
    Keam SJ
    Drugs; 2023 May; 83(7):633-638. PubMed ID: 37022666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.
    Dargaud Y; Leuci A; Ruiz AR; Lacroix-Desmazes S
    Haematologica; 2024 Aug; 109(8):2436-2444. PubMed ID: 38356459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
    Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA; Shapiro AD; Quon DV; Staber JM; Kulkarni R; Ragni MV; Chhabra ES; Poloskey S; Rice K; Katragadda S; Fruebis J; Benson CC
    N Engl J Med; 2020 Sep; 383(11):1018-1027. PubMed ID: 32905674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
    Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
    Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.